These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36746274)

  • 1. Isolation of OXA-48-like carbapenemase-producing Escherichia coli susceptible to piperacillin/tazobactam in a Japanese patient without a history of travel abroad.
    Kaneko M; Masuda Y; Sawachika H; Shikata H; Moriyama C; Miura M; Yamamoto H; Nakamura T; Fukumoto K; Utsunomiya Y; Sakai K; Ito Y; Ujike A; Asano Y; Shinomiya H
    J Infect Chemother; 2023 May; 29(5):530-533. PubMed ID: 36746274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-Relebactam Susceptibility in
    Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
    Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete sequence of carbapenem-resistant
    Hayashi W; Kaiju H; Kayama S; Yu L; Zuo H; Sugawara Y; Azuma K; Takahashi A; Hata Y; Sugai M
    Microbiol Spectr; 2024 Apr; 12(4):e0391923. PubMed ID: 38483476
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
    Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Piperacillin-Tazobactam-Meropenem Synergy against Serine Carbapenemase-Producing
    Lawandi A; Leite GC; Cheng MP; Lefebvre B; Longtin J; Lee TC
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Resistance Pattern and Genetic Characteristics of ESBL and Carbapenemase-producing Escherichia coli at a Tertiary Care Hospital in Bangladesh.
    Khan ER; Paul SK; Kobayashi N; Khan TR; Rahman MH; Rahman MM
    Mymensingh Med J; 2020 Jan; 29(1):37-42. PubMed ID: 31915333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
    Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae from Bangkok, Thailand, and Their Detection by the Carba NP and Modified Carbapenem Inactivation Method Tests.
    Laolerd W; Akeda Y; Preeyanon L; Ratthawongjirakul P; Santanirand P
    Microb Drug Resist; 2018 Sep; 24(7):1006-1011. PubMed ID: 29782216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of β-lactamases and emergence of carbapenemases co-occurring Enterobacterales isolates with high-level antibiotic resistance identified from patients with intra-abdominal infection in the Asia-Pacific region, 2015-2018.
    Chen YC; Chen WY; Hsu WY; Tang HJ; Chou Y; Chang YH; Chen CC; Chuang YC; Chang TH
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1263-1272. PubMed ID: 34330663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and genotypic distribution of ESBL, AmpC β-lactamase and carbapenemase-producing Enterobacteriaceae in community-acquired and hospital-acquired urinary tract infections in Sri Lanka.
    Perera PDVM; Gamage S; De Silva HSM; Jayatilleke SK; de Silva N; Aydin A; Enne VI; Corea EM
    J Glob Antimicrob Resist; 2022 Sep; 30():115-122. PubMed ID: 35667644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the modified Hodge test and the Carba NP test for detection of carbapenemases in Enterobacteriaceae isolates].
    Bayramoğlu G; Uluçam G; Gençoğlu Özgür Ç; Kılıç AO; Aydın F
    Mikrobiyol Bul; 2016 Jan; 50(1):1-10. PubMed ID: 27058324
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
    Wu AY; Chang H; Wang NY; Sun FJ; Liu CP
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating NG-Test CARBA 5 Multiplex Immunochromatographic and Cepheid Xpert CARBA-R Assays among Carbapenem-Resistant
    Huang YT; Kuo YW; Lee NY; Tien N; Liao CH; Teng LJ; Ko WC; Hsueh PR;
    Microbiol Spectr; 2022 Feb; 10(1):e0172821. PubMed ID: 35019772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse efficacy of CarbaNP test among OXA-48 carbapenemase producing Enterobacterales in an endemic region.
    Hortaç İştar E; Alışkan HE; Göçmen JS
    Acta Microbiol Immunol Hung; 2021 Mar; 68(1):34-39. PubMed ID: 33661134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OXA-48-like carbapenemases in
    Sattler J; Noster J; Stelzer Y; Spille M; Schäfer S; Xanthopoulou K; Sommer J; Jantsch J; Peter S; Göttig S; Gatermann SG; Hamprecht A
    Emerg Microbes Infect; 2024 Dec; 13(1):2353310. PubMed ID: 38712879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.